Journal of Clinical Psychopharmacology最新文献

{"title":"Long-Term Misuse of Megestrol Acetate Associated With Immunocompromise, Complicated by Esophageal Candidiasis, Hypogonadism, and Adrenal Insufficiency in Treatment-Resistant Depression.","authors":"Hsin Fang, Chih-Chung Huang, Chia-Yi Yao, Shin-Chang Kuo, Chun-Yen Chen, Chia-Ling Chen, Yi-Wei Yeh","doi":"10.1097/JCP.0000000000001983","DOIUrl":"10.1097/JCP.0000000000001983","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"525-527"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Discontinuation of Clozapine Due to Serious Side Effects: A Retrospective Cohort Study.","authors":"Doğukan Koçyiğit, Rukiye Aktaş, Selim Coşkun, Elçin Özçelik Eroğlu, Emre Mutlu, Ayşe Elif Anil Yağcioğlu","doi":"10.1097/JCP.0000000000002035","DOIUrl":"10.1097/JCP.0000000000002035","url":null,"abstract":"<p><strong>Background: </strong>Clozapine remains underutilized due to its serious side effects, leading to negative prescriber attitudes. We aim to elaborate on serious side effects and discontinuation of clozapine in patients followed up in our center for 12 years.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of patients admitted to the tertiary inpatient psychiatry service between 2010 and 2022. The cohort included patients with psychotic disorders (PD) or bipolar affective disorders (BAD), who discontinued clozapine during their hospitalization due to serious side effects. Rechallenge attempts and clinical outcomes after discontinuation were recorded.</p><p><strong>Results: </strong>Among 2298 patients, 568 (178 clozapine users, prescribing rate: 31.3%) were diagnosed with PD, and 420 (21 clozapine users, prescribing rate: 5%) were diagnosed with BAD. Fourteen patients with PD and 3 patients with BAD had a serious side effect of clozapine, which resulted in discontinuation in 15 patients (7.53%). The most frequent serious side effects were myocarditis or suspected myocarditis (5.02%) and agranulocytosis (1.50%). There was no sudden death, cardiac arrest, or need for intensive care. Of serious side effects, 88.2% occurred within 6 months after clozapine initiation. The most switched antipsychotic was olanzapine (57.1%) after discontinuation. Among those whose clozapine was discontinued, 20% of the patients were rechallenged, of which 66.6% were successful.</p><p><strong>Conclusions: </strong>Twelve years of observation shows that even life-threatening side effects of clozapine can be managed successfully. Our findings support that physicians should not miss patients' opportunities to benefit from clozapine due to their concern about serious side effects. Lastly, rechallenge is an option even if serious side effects occur in certain conditions.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"479-483"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase 2 Randomized Trial of NBI-1065846 (TAK-041) in Patients With Anhedonia Associated With Major Depressive Disorder: Results of the TERPSIS Study.","authors":"Shannon R Benedetto, Adrian Ionescu, Tingting Ge, Maura Furey, Swan Lin, Manish K Jha, Andrew Krystal, Asim A Shah, David P Walling, Neel Shah, Sakina J Rizvi, Sidney Kennedy, Antonio Laurenza, Venkatesha Murthy, Eiry Roberts, Jaskaran B Singh","doi":"10.1097/JCP.0000000000002046","DOIUrl":"10.1097/JCP.0000000000002046","url":null,"abstract":"<p><strong>Background: </strong>Anhedonia is a core symptom of major depressive disorder (MDD) that may result from aberrant lateral habenula hyperactivity. Targeting G-protein coupled receptor 139 (GPR139) may improve anhedonia by modulating lateral habenula activity. NBI-1065846 is an investigational GPR139 agonist that improved anhedonia, anxiety, and depression in rodent models.</p><p><strong>Methods: </strong>TERPSIS was a phase 2, proof-of-concept clinical study. Adults with MDD experiencing a major depressive episode with anhedonia were randomized 1:1 to NBI-1065846 or placebo for 8 weeks. The primary endpoint was the change in the Dimensional Anhedonia Rating Scale (DARS) score. Secondary endpoints were change in total Montgomery Åsberg Depression Rating Scale (MADRS) score in participants with a baseline 17-item Hamilton Depression Rating Scale (HAM-D17) score of ≥19 (moderate to severe) and change in Clinical Global Impression of Severity (CGI-S) score. All changes were from baseline to Day 57.</p><p><strong>Results: </strong>In total, 93 participants received study treatment (NBI-1065846, n = 46; placebo, n = 47). Both groups showed notable improvements in DARS scores from baseline to day 57 (least-squares mean change: NBI-1065846, 13.5; placebo, 17.4), with no statistically significant difference (NBI-1065846 vs. placebo, P = 0.8663). Similarly, MADRS ( P = 0.7008) and CGI-S ( P = 0.9051) scores showed no significant difference between groups. All treatment-emergent adverse events in the NBI-1065846 group were mild or moderate in severity.</p><p><strong>Conclusions: </strong>The TERPSIS study did not meet its primary or secondary endpoints. NBI-1065846 was generally well tolerated. Addressing the lack of treatment options for anhedonia remains an important unmet clinical need.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"432-440"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia.","authors":"Gavin P Reynolds","doi":"10.1097/JCP.0000000000002028","DOIUrl":"10.1097/JCP.0000000000002028","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"529-530"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blepharospasm Arising From Escitalopram Use: A Case Report.","authors":"Anastasia Zent, Sean Nutting","doi":"10.1097/JCP.0000000000002043","DOIUrl":"10.1097/JCP.0000000000002043","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"515-516"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant Use of Dextromethorphan/Bupropion and Escitalopram Associated With Serotonin Toxicity in an Older Adult: A Case Report.","authors":"Demetrius Woodard, Lara Boyle, Samantha J Zwiebel","doi":"10.1097/JCP.0000000000002034","DOIUrl":"10.1097/JCP.0000000000002034","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"509-511"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Ziconotide-Associated Delirium and Psychosis: A Case Report.","authors":"Greg Noe, Arlen Gaba, Sahil Munjal","doi":"10.1097/JCP.0000000000002021","DOIUrl":"10.1097/JCP.0000000000002021","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"516-518"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Call for the Study of Zuranolone as a Novel Treatment for Premenstrual Dysphoric Disorder.","authors":"Zoya Munsar, Douglas Opler","doi":"10.1097/JCP.0000000000002026","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002026","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"45 5","pages":"533-534"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.","authors":"Guy Ludbrook, Nathan Bryson, Beatrix Taylor, Jasna Hocevar-Trnka, Matthew W Johnson, Joe Hirman, Glynn Morrish, Robert Alexander, Mark Pollack","doi":"10.1097/JCP.0000000000002047","DOIUrl":"10.1097/JCP.0000000000002047","url":null,"abstract":"<p><strong>Background: </strong>This study is the first to formally evaluate in humans the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RE104, a prodrug of the synthetic psychedelic known as 4-hydroxy-N,N-diisopropyltryptamine or 4-OH-DiPT.</p><p><strong>Methods: </strong>This double-blind, randomized, placebo-controlled, phase 1 study of single subcutaneous (SC) doses of RE104 (5 to 40 mg) included 6 cohorts and a total of 48 healthy adult participants with prior experiences with hallucinogenic or psychedelic compounds.</p><p><strong>Results: </strong>SC doses of RE104 were generally safe up to 40 mg with no serious adverse events (AEs) or deaths. Most AEs occurred acutely under supervision and were mild to moderate. The Columbia-Suicide Severity Rating Scale score did not increase during the study, and the Assessment of Alertness and Sedation Scale was largely normal at all timepoints regardless of dose. RE104 exposure, based on Cmax, AUC 0-t , and AUC 0-inf , increased with dose from 5 to 40 mg RE104. 4-OH-DiPT appeared rapidly in plasma (median T max ranged from 1.0 to 1.25 hours across dose groups). Mean plasma 4-OH-DiPT t ½ ranged from 2.72 hours to 4.12 hours. PKs appeared linear at the doses examined. Plasma levels of 4-OH-DiPT correlated with the Drug Effect Questionnaire and Mystical Experience Questionnaire (MEQ). Dose-related increases were observed in frequency of the MEQ 30 \"complete mystical experience\" responders.</p><p><strong>Conclusions: </strong>Single SC doses of RE104 resulted in a psychoactive experience and a favorable safety profile similar to psilocybin but with a shorter duration of psychoactive effect (3 to 4 hours). Results suggest a potential for therapeutic effect, warranting further study.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"441-453"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression? A VAST-D Report.","authors":"Sidney Zisook, Gary R Johnson, Beata Planeta, Somaia Mohamed","doi":"10.1097/JCP.0000000000002051","DOIUrl":"10.1097/JCP.0000000000002051","url":null,"abstract":"<p><strong>Background: </strong>Many patients view the return of \"positive mental health\" (PMH) to be their most important goal of treatment for major depressive disorder (MDD). However, few studies have systematically measured PMH or prospectively examined the added value of considering PMH as a treatment predictor of outcome. This report aims to fill those gaps by determining features associated with PMH and their contributions to outcomes in outpatients with treatment-resistant depression.</p><p><strong>Methods: </strong>The VA Augmentation and Switching Treatments for Depression trial randomized 1522 participants to 1 of 3 next-step treatments: switching to bupropion (S-BUP), combining with bupropion (C-BUP), or augmenting with aripiprazole (A-ARI). PMH was measured by a novel, 7-item, self-rated questionnaire. The features and outcomes associated with PMH at baseline and during 12 weeks of treatment were explored.</p><p><strong>Results: </strong>Low PMH scores at baseline were associated with greater severity and chronicity of depression, suicidal ideation, increased anxiety, comorbid PTSD, grief, and lower quality of life. High PMH scores were associated with a greater likelihood of remission. PMH scores improved with treatment, especially if the next-step treatment was A-AUG as opposed to S-BUP. Improvement in PMH was associated with higher remission and response rates.</p><p><strong>Conclusions: </strong>Targeting deficiencies in PMH could help optimize outcomes in patients with MDD.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov identifier NCT01421342.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"421-431"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}